IGFBP2 and metastatic neoplasm: Concerning the possibility to use biomarkers as determinant of patients outcome, we found that blood levels of IGFBP2 protein and autoantibodies effectively distinguished children with metastatic disease at diagnosis into a more favorable and unfavorable prognosis group, whereas they did not have the same significance in patients with localized disease at diagnosis.